Australian veterinary drug developer Nexvet racks up $31.5 mln

Nexvet Biopharma has closed $31.5 million in Series B financing. Investors included Farallon Capital Management, Adage Capital Partners, Foresite Capital and Tavistock Life Sciences subsidiary fund Boxer Capital. Based in Melbourne, Australia, Nexvet is a veterinary biologic drug developer.

124 Views

Boston biotech firm Intarcia snags $200 mln

Boston-based biotech company Intarcia Therapeutics has raised $200 million financing. RA Capital led the round with participation from investors that include Farallon Capital Management, Foresite Capital, Franklin Templeton, Fred Alger Management, New Leaf Venture Partners and Quilvest.

New Ownership For Contech

Contech has announced its new owners. Investors Anchorage Capital Group, Littlejohn & Co, Tennenbaum Capital Partners, and Farallon Capital Management have worked with Contech, its equity partners and its senior lenders to recapitalize the company and secure long-term financing. Contech is a provider of site solution products and services for the civil engineering industry. PRESS […]

PEHUB Community

Join the 12500 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget